JPMorgan raised the firm’s price target on Syndax (SNDX) to $41 from $39 and keeps an Overweight rating on the shares after having surveyed 23 U.S. hematologists to better understand the launch prospects of Revuforj in relapsed/refractory KMT2A acute leukemias and NPM1-mutated acute myeloid leukemia. Overall, surveyed physicians provided high ratings related to the clinical profile of Revuforj in both indications, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Strong Buy Rating for Syndax Pharmaceuticals Driven by Revuforj’s Market Potential and Revenue Growth
- Positive Outlook on Syndax Pharmaceuticals: Strong Market Presence and Strategic Growth Initiatives
- Syndax price target raised to $39 from $35 at JPMorgan
- Syndax price target lowered to $42 from $45 at Citi
- Promising Outlook for Syndax Pharmaceuticals: Buy Rating Supported by Revuforj Launch and Strategic Positioning